SCLX

Scilex Holding Co. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Scilex Holding Company (SCLX) is a biopharmaceutical firm focused on non-opioid pain management products, including ZTlido, ELYXYB, and GLOPERBA. The company also maintains a significant cryptocurrency treasury strategy (Bitcoin) and holds equity method investments in Datavault AI Inc. and Vivasor Holding Company. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: The filing text does not provide a clear value for Q1 2025 working capital.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased by $3.6 million (72%) driven by higher sales of ZTlido ($1.1M increase) and new contract revenue from Vivasor ($2.4M). GLOPERBA revenue declined slightly.
• Operating Expenses: Total operating costs rose to $40.8 million from $32.9 million. Selling, General, and Administrative (SG&A) expenses increased by $3.0 million, primarily due to advisory and financing costs.
• Investment Volatility: The company recorded a $42.3 million realized gain on the sale of Datavault shares, offset by a $31.7 million unrealized loss on remaining Datavault holdings and an $18.1 million unrealized loss on digital assets (Bitcoin).
• Debt Restructuring: The Scilex-St. James Loan Agreement was terminated on March 16, 2026, following a dispute over pledged Datavault shares. This resulted in a $21.8 million loss on the compound derivative but no gain or loss on debt extinguishment.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year following the issuance date. This is due to recurring losses, negative cash flows, and an accumulated deficit of $965.1 million.
• Liquidity Strategy: The company plans to fund operations through equity offerings, debt financings, and strategic transactions. It continues to pursue a cryptocurrency treasury strategy, holding 955 Bitcoin units valued at $65.3 million.
• Legal Proceedings:
  • St. James Lawsuit: Scilex filed a complaint seeking over $100 million in damages against St. James Bank & Trust and BNY Mellon regarding the unauthorized sale of pledged Datavault shares.
  • Patent Litigation: Scilex is appealing a Federal Circuit decision regarding ZTlido patent infringement.
  • Sorrento Litigation: Former Sorrento equity holders filed a complaint alleging wrongful conduct regarding Sorrento's bankruptcy proceedings.
• Subsequent Events: Following the quarter end, the company announced a $1.0 billion stock acquisition agreement involving its subsidiary ACEA Therapeutics and Phoenix Asia Holdings Limited. Additionally, the Oramed Note maturity was extended to June 15, 2026.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.4 million cash balance against immediate debt obligations, specifically the Oramed Note and Tranche B Notes.
• Datavault Exposure: Assess the impact of the terminated St. James loan and the ongoing litigation on the valuation of the remaining Datavault equity method investment ($79.1 million).
• Cryptocurrency Volatility: Monitor the fair value of the $65.3 million Bitcoin holding, which contributed significantly to the period's unrealized losses.
• Debt Covenants: Review the terms of the Oramed Note and Tranche B Notes for potential default triggers given the company's liquidity position.
• Going Concern Mitigation: Evaluate the feasibility of the company's stated plans to raise additional capital to sustain operations for the next 12 months.